Associations - HRAS mutation

BIOMARKER:

HRAS mutation

Entrez ID:

3265

Related biomarkers:

Mutation

Others

‹

›

HRAS mutation HRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
HRAS mutation HRAS mutation	Urothelial Cancer Urothelial Cancer	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2
HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
HRAS mutation HRAS mutation	Colorectal Cancer CRC	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
HRAS mutation HRAS mutation	Colorectal Cancer CRC	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3
HRAS mutation HRAS mutation	Salivary Gland Cancer Salivary Gland Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
HRAS mutation HRAS mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
HRAS mutation HRAS mutation	Acute Myelogenous Leukemia AML	mTOR inhibitor Resistant: D – Preclinical mTOR inhibitor Resistant : D
HRAS mutation HRAS mutation	Rhabdomyosarcoma Rhabdomyosarcoma	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS mutation HRAS mutation	Endometrial Cancer Endometrial Cancer	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D
HRAS mutation HRAS mutation	Endometrial Cancer Endometrial Cancer	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
HRAS mutation HRAS mutation	Bladder Cancer Bladder Cancer	FL118 Sensitive: D – Preclinical FL118 Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES